Healthcare / Medical DevicesXETRA
$6.80
+0.10 (+1.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$138M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1.1%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-226368.1 · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-226368.08 | $-226368.08 | $-110411.67 | $-160617.30 | $-5019.95 |
| EBITDA | $-212546.90 | $-212546.90 | $-108958.23 | $-160474.10 | $-5019.95 |
| EPS | -0.01 | -0.01 | — | — | -0.00 |
| Returns | |||||
| ROE | -1.1% | -1.1% | -0.6% | -0.8% | -2.0% |
| Valuation | |||||
| P/B | 6.97 | 6.97 | — | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+78.9%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → -0.01
Residual
+78.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.